UBS AM
BPMC

UBS AM’s Blueprint Medicines BPMC Stock Holding History

UBS AM’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-215,946
Closed -$27.7M – 2329
2025
Q2 		$27.7M Sell
215,946
-28,465
-12% -$2.96M 0.01% 914
2025
Q1 		$21.6M Buy
244,411
+4,465
+2% +$436K 0.01% 929
2024
Q4 		$20.9M Buy
239,946
+12,035
+5% +$1.1M ﹤0.01% 925
2024
Q3 		$21.1M Sell
227,911
-73,962
-25% -$7.35M 0.01% 926
2024
Q2 		$32.5M Buy
301,873
+67,258
+29% +$6.73M 0.01% 720
2024
Q1 		$22.3M Sell
234,615
-4,558
-2% -$391K 0.01% 762
2023
Q4 		$22.1M Sell
239,173
-3,019
-1% -$196K 0.01% 746
2023
Q3 		$12.2M Sell
242,192
-10,157
-4% -$543K 0.01% 890
2023
Q2 		$11.4M Hold
252,349
– – 0.01% 922
2023
Q1 		$11.4M Sell
252,349
-9,336
-4% -$421K 0.01% 922
2022
Q4 		$11.5M Sell
261,685
-6,790
-3% -$326K 0.01% 893
2022
Q3 		$17.7M Sell
268,475
-11,887
-4% -$763K 0.01% 791
2022
Q2 		$14.2M Buy
280,362
+40,386
+17% +$2.37M 0.01% 838
2022
Q1 		$15.3M Buy
239,976
+5,369
+2% +$385K 0.01% 921
2021
Q4 		$25.1M Sell
234,607
-26,474
-10% -$2.77M 0.01% 844
2021
Q3 		$26.8M Sell
261,081
-21,288
-8% -$1.98M 0.01% 793
2021
Q2 		$24.8M Buy
282,369
+24,204
+9% +$2.22M 0.01% 833
2021
Q1 		$25.1M Sell
258,165
-79,837
-24% -$7.97M 0.01% 806
2020
Q4 		$37.9M Buy
338,002
+37,040
+12% +$3.9M 0.02% 676
2020
Q3 		$27.9M Buy
300,962
+21,750
+8% +$1.67M 0.02% 679
2020
Q2 		$21.8M Buy
279,212
+187,039
+203% +$12.7M 0.01% 717
2020
Q1 		$5.39M Sell
92,173
-45,679
-33% -$2.94M ﹤0.01% 1028
2019
Q4 		$11M Buy
137,852
+1,910
+1% +$143K 0.01% 910
2019
Q3 		$9.99M Buy
135,942
+3,834
+3% +$331K 0.01% 959
2019
Q2 		$12.5M Buy
132,108
+1,953
+2% +$161K 0.01% 892
2019
Q1 		$10.4M Buy
130,155
+4,419
+4% +$327K 0.01% 925
2018
Q4 		$6.78M Sell
125,736
-7,883
-6% -$479K 0.01% 975
2018
Q3 		$10.4M Buy
133,619
+6,739
+5% +$468K 0.01% 924
2018
Q2 		$8.05M Buy
126,880
+18,876
+17% +$1.5M 0.01% 996
2018
Q1 		$9.9M Sell
108,004
-1,784
-2% -$154K 0.01% 932
2017
Q4 		$8.28M Buy
109,788
+1,125
+1% +$79.2K 0.01% 964
2017
Q3 		$7.57M Buy
108,663
+95,612
+733% +$5.11M 0.01% 968
2017
Q2 		$661K Buy
13,051
+8,036
+160% +$341K ﹤0.01% 1800
2017
Q1 		$201K Buy
+5,015
New +$180K ﹤0.01% 2192
2016
Q4 		– Sell
-11,015
Closed -$327K – 2521
2016
Q3 		$327K Buy
11,015
+915
+9% +$22.7K ﹤0.01% 2218
2016
Q2 		$205K Hold
10,100
– – ﹤0.01% 2433
2016
Q1 		$182K Sell
10,100
-114,331
-92% -$1.98M ﹤0.01% 2457
2015
Q4 		$3.28M Sell
124,431
-10,490
-8% -$236K ﹤0.01% 1220
2015
Q3 		$2.88M Buy
134,921
+15,642
+13% +$433K ﹤0.01% 1262
2015
Q2 		$3.16M Buy
+119,279
New +$3.41M ﹤0.01% 1207

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

UBS AM's BPMC Position: Q3 2025 in Review

UBS AM sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 215,946 shares — an estimated $27.7M sold.

UBS AM first reported a position in BPMC in Q2 2015 and held it in 40 quarters. The position peaked at $37.9M in Q4 2020. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • UBS AM reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • UBS AM sold 215,946 Blueprint Medicines shares in Q3 2025, an estimated $27.7M.
  • UBS AM first reported a position in Blueprint Medicines in Q2 2015 and held it in 40 quarters.
  • UBS AM's Blueprint Medicines position peaked at $37.9M in Q4 2020.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on UBS AM's 13F filing for Q3 2025, filed 14 Nov 2025.